Ventyx Biosciences, Inc. corporate insiders have only been selling lately: two insiders unloaded about $463,000 of stock over 12 months, with no open-market purchases.
That's worth context: executives sell for plenty of routine reasons, from scheduled trading plans to tax bills. Buying is the rarer, more telling signal.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Dec 19, 2025 | Mohan Raju | CEO | Sell | 47,345 | $7.72 | $366K | SEC |
| Dec 19, 2025 | Nuss John | Executive Officer | Sell | 12,675 | $7.72 | $98K | SEC |
| Apr 3, 2025 | Nuss John | Executive Officer | Sell | 1,887 | $1.07 | $2K | SEC |
| Dec 30, 2024 | Nuss John | Executive Officer | Sell | 21,119 | $2.36 | $50K | SEC |
| Dec 26, 2024 | Gujrathi Sheila | Director | Buy | 130,000 | $2.31 | $300K | SEC |
| Dec 19, 2024 | Nuss John | Executive Officer | Sell | 13,161 | $2.26 | $30K | SEC |
| Nov 25, 2024 | Mohan Raju | CEO | Buy | 261,752 | $2.01 | $526K | SEC |
| Nov 25, 2024 | Mohan Raju | CEO | Buy | 238,248 | $1.83 | $436K | SEC |
| Apr 3, 2024 | Krueger Christopher W | Executive Officer | Sell | 1,651 | $5.40 | $9K | SEC |
| Apr 3, 2024 | Nuss John | Executive Officer | Sell | 1,651 | $5.40 | $9K | SEC |
| Apr 3, 2024 | Mohan Raju | CEO | Sell | 4,312 | $5.40 | $23K | SEC |
| Apr 3, 2024 | Auster Martin | CFO | Sell | 1,405 | $5.40 | $8K | SEC |
| Oct 11, 2023 | NSV Partners III GP LLC | 10% Owner | Sell | 49,152 | $30.03 | $1.5M | SEC |
| Oct 11, 2023 | Subramaniam Somu | Director | Sell | 49,152 | $30.03 | $1.5M | SEC |
| Oct 6, 2023 | Mohan Raju | CEO | Sell | 30,000 | $29.11 | $873K | SEC |
In the last 12 months Ventyx Biosciences, Inc. insiders made open-market purchases worth about $0 and sales worth about $463,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in VTYX was filed on 2025-12-19.
No congressional trades in VTYX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).